Nexstim Plc Signs an Independent Selling Representative Agreement in the U.S. with JTec Surgical, Inc.

Press release, Helsinki, 22 March 2017 at 3 pm

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company with a pioneering navigated non-invasive brain stimulation system, announces that its wholly owned subsidiary Nexstim Inc. has signed a new Independent Selling Representative Agreement in the U.S. with JTec Surgical, Inc.  to represent the Nexstim Brain Mapping (NBS) system. The NBS system is used for the pre-surgical mapping of the speech and motor cortices of the brain. 

JTec Surgical will cover the Southern California region, where it has established a strong presence and relationships in the neurosurgical technology space for more than 25 years.  The JTec portfolio includes a number of carefully selected and innovative products for neurosurgical procedures.  

Commenting on the event, John Liedtky, General Manager U.S. stated: "The Nexstim commercial strategy continues to progress well, as I am very pleased that we have added JTec Surgical, Inc to the team of U.S.  Independent Selling Representatives for the Nexstim NBS Brain Mapping technology.  We look forward to collaborating with our new Southern Californian partner to drive further market adoption of this impactful and valuable technology"

NEXSTIM PLC
Martin Jamieson, Chairman and CEO

Further information is available on the website www.nexstim.com or by telephone:

Nexstim                                                                  +447715163942
Martin Jamieson, Chairman and CEO [email protected]

Citigate Dewe Rogerson                               +44 (0)207 2821066
Katja Stout                                            [email protected]

About Nexstim Plc
Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system. It is the first and only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE marked for the treatment of chronic neuropathic pain, major depression and stroke. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/f238a268-3627-4efb-8195-aa14c7a01669